ACRX
NASDAQAcelRx Pharmaceuticals Inc.
News · 26 weeks1-100%
2025-12-072026-05-31
Mix190d
- Other1(100%)
Latest news
25 items- PRTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company's next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company's 2026 Annual Meeting of Stockholders on June 9, 2026 (the "2026 Annual Meeting"), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial strategy,
- 13D/GSEC Form SC 13G/A filed by AcelRx Pharmaceuticals Inc. (Amendment)SC 13G/A - TALPHERA, INC. (0001427925) (Subject)
- SECSEC Form EFFECT filed by AcelRx Pharmaceuticals Inc.EFFECT - TALPHERA, INC. (0001427925) (Filer)
- INSIDERDasu Badri N covered exercise/tax liability with 1,618 shares, decreasing direct ownership by 9% to 17,153 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERPalmer Pamela P covered exercise/tax liability with 1,602 shares, decreasing direct ownership by 4% to 35,344 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERAsadorian Raffi covered exercise/tax liability with 1,790 shares, decreasing direct ownership by 8% to 20,291 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERAngotti Vincent J. covered exercise/tax liability with 7,043 shares, decreasing direct ownership by 7% to 94,762 units (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- 13D/GSEC Form SC 13G/A filed by AcelRx Pharmaceuticals Inc. (Amendment)SC 13G/A - TALPHERA, INC. (0001427925) (Subject)
- SECSEC Form 424B7 filed by AcelRx Pharmaceuticals Inc.424B7 - TALPHERA, INC. (0001427925) (Filer)
- SECSEC Form S-3 filed by AcelRx Pharmaceuticals Inc.S-3 - TALPHERA, INC. (0001427925) (Filer)
- SECSEC Form D filed by AcelRx Pharmaceuticals Inc.D - TALPHERA, INC. (0001427925) (Filer)
- INSIDERSEC Form 4 filed by Nantahala Capital Management, Llc4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERJain Abhinav was granted 871 shares (SEC Form 4)4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERSEC Form 3 filed by new insider Jain Abhinav3 - TALPHERA, INC. (0001427925) (Issuer)
- 13D/GSEC Form SC 13D filed by AcelRx Pharmaceuticals Inc.SC 13D - TALPHERA, INC. (0001427925) (Subject)
- SECAcelRx Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TALPHERA, INC. (0001427925) (Filer)
- INSIDERNew insider Nantahala Capital Management, Llc claimed ownership of 1,237,519 shares (SEC Form 3)3 - TALPHERA, INC. (0001427925) (Issuer)
- SECAcelRx Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - TALPHERA, INC. (0001427925) (Filer)
- SECAcelRx Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TALPHERA, INC. (0001427925) (Filer)
- NEWSAcelRx Pharmaceuticals Announces Rebranding With Name Change to Talphera; To Trade On Nasdaq Under Ticker Symbol "TLPH" Effective Jan. 10, 2024Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settingsTalphera will begin trading on Nasdaq under the trading symbol "TLPH" effective January 10
- PRAcelRx Announces Rebranding With Name Change to Talphera, Inc.Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on Nasdaq under the trading symbol "TLPH" effective January 10 SAN MATEO, Calif., Jan. 9, 2024 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the rebranding of the Company, with a name change to Talphera, Inc. ("Talphera"). The rebrand decision was made to reflect the Company's strategy of developing and commercializin
- INSIDERAngotti Vincent J. bought $7,268 worth of shares (10,000 units at $0.73), increasing direct ownership by 11% to 101,805 units (SEC Form 4)4 - ACELRX PHARMACEUTICALS INC (0001427925) (Issuer)
- INSIDERHoffman Stephen J was granted 581 shares, increasing direct ownership by 32% to 2,418 units (SEC Form 4)4 - ACELRX PHARMACEUTICALS INC (0001427925) (Issuer)
- INSIDERAfable Richard was granted 581 shares, increasing direct ownership by 31% to 2,468 units (SEC Form 4)4 - ACELRX PHARMACEUTICALS INC (0001427925) (Issuer)
- INSIDERWan Mark A was granted 581 shares, increasing direct ownership by 32% to 2,418 units (SEC Form 4)4 - ACELRX PHARMACEUTICALS INC (0001427925) (Issuer)
ACRX FAQ
7 questionsWhat does AcelRx Pharmaceuticals Inc. do?
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx...Where does ACRX stock trade?
AcelRx Pharmaceuticals Inc. (ACRX) is listed on NASDAQ.What sector and industry is ACRX in?
AcelRx Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AcelRx Pharmaceuticals Inc. go public?
AcelRx Pharmaceuticals Inc. (ACRX) completed its IPO in 2011.What are analysts saying about ACRX?
AcelRx Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $500.00 price target on 2021-08-17. Recent price targets cluster around $500.00.What companies are similar to ACRX?
Notable peers in the same industry include COLL (Collegium Pharmaceutical Inc.), MRNS (Marinus Pharmaceuticals Inc.), SPPI (Spectrum Pharmaceuticals Inc.), CPIX (Cumberland Pharmaceuticals Inc.), ARDS (Aridis Pharmaceuticals Inc.). Compare ACRX side-by-side with any of them on Quantisnow.How can I track ACRX on Quantisnow?
Quantisnow aggregates AcelRx Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACRX to receive live email and push alerts on every new disclosure.